Chip Stock Investor Podcast

Nicholas Rossolillo; Kasey Rossolillo
  • 4.6 (14)
  • Investing
  • Updated Weekly

Semiconductors are the heart of the modern economy. These small devices that manipulate the flow of electricity run everything from our PCs and smartphones to our cars to manufacturing. The semiconductor industry is at an inflection point of renewed growth, powering new movements like generative AI and electric vehicles. The Chip Stock Investor Podcast explores how semiconductors work, and especially the business of chips. Follow Nicholas and Kasey to learn how chip technology has become the engine of the world, and how to invest in its growth.

  1. 2d ago

    Nvidia's Biggest Acquisition Ever: $12.9B for Hugging Face (Can It Survive Regulators?)

    Nvidia just proposed its largest acquisition ever — $12.9 billion for Hugging Face. But regulators in the US, EU, and China may have other plans. Nvidia has announced plans to acquire Hugging Face, the leading open-source repository for AI and machine learning code, in a deal valued at $12.9 billion — technically the largest acquisition in Nvidia's history. In this episode, we break down what Hugging Face actually does, why it matters to Nvidia's broader ecosystem strategy, and how this move fits into Nvidia's history of vertical and horizontal acquisitions, from Mellanox to the failed Arm Holdings bid. We also examine the growing trend of "acquihires" (Enfabrica, Groq, Poolside) and what regulatory scrutiny could mean for this deal specifically, given Hugging Face's large presence in the EU. We draw a direct comparison to Microsoft's 2018 acquisition of GitHub — and how that deal quietly became a distribution funnel for Azure and OpenAI — then ask whether Hugging Face could play a similar role for Nvidia's AI infrastructure business. Finally, we cover Nvidia's revenue segmentation shift, its position versus Broadcom, and why this remains our top semiconductor holding heading into the rest of 2026. TIMESTAMPS0:00 - Nvidia's $12.9B Hugging Face Bombshell1:00 - What Hugging Face Actually Does2:30 - Why Nvidia Wants Developer Distribution4:00 - Nvidia's Acquisition Track Record: Mellanox to Arm5:30 - The Rise of the "Acquihire" (Enfabrica, Groq, Poolside)6:30 - Regulatory Risk: Why This Deal Could Get Blocked8:00 - The Microsoft-GitHub Playbook Comparison11:00 - Nvidia's Revenue Segmentation Shift13:00 - Nvidia vs. Broadcom: Growth Comparison14:00 - Valuation and Final Take for 2026 — If you want the reasoning behind more names like this one, Semiconductor Insider covers the process in more depth. Get access to all our research, weekly live Q&A events, and a growing set of tools to build your process: https://www.chipstockinvestor.com All our socials: https://linktr.ee/chipstockinvestor If you're getting value from the show, follow so you don't miss the next one. — Disclosure: Some links above are affiliate links. If you buy something through them, we might earn a little coffee money — thanks for helping us (Kasey) fuel our caffeine addiction. Content in this episode is for general information or entertainment only and is not specific or individual investment advice. Forecasts and information presented may not develop as predicted, and there is no guarantee any strategies presented will be successful. All investing involves risk, and you could lose some or all of your principal. CSI owns shares of Nvidia.

    Nvidia's Biggest Acquisition Ever: $12.9B for Hugging Face (Can It Survive Regulators?)

  2. 2d ago

    Pure Storage Is Now Everpure — and Free Cash Flow Just Went Negative (P Stock)

    Pure Storage just rebranded to Everpure — and in the same stretch, free cash flow went negative 20% in a single quarter. Here's what's really going on. Pure Storage has officially rebranded as Everpure (P), reflecting its shift from a storage-hardware company into a broader enterprise data management platform. In this episode, we break down what the rebrand actually signals about the business, then dig into the numbers behind a rough quarter: free cash flow swung negative as the company prepaid roughly $500 million for NAND flash and memory components amid a broader memory shortage. We map where Everpure sits in the semiconductor and data center supply chain, its suppliers (Micron, Kioxia), and its closest public peer, NetApp — comparing revenue growth, gross margin, and free cash flow margin side by side. We also unpack Everpure's growing hyperscaler relationships, including its Meta partnership and a newly disclosed second hyperscaler customer, and what that means for growth heading into fiscal 2028. Finally, we run a reverse DCF at current prices to show exactly what growth and margin assumptions the market is pricing in — and whether this could be a durable, long-term compounder. TIMESTAMPS0:00 - Pure Storage Is Now Everpure — Why the Rebrand Happened1:15 - Where Everpure Fits in the Semiconductor Supply Chain5:00 - Suppliers, Competitors, and the Rise of Vast Data7:00 - The Meta Deal and Second Hyperscaler Explained9:00 - Everpure vs. NetApp: Margins and Growth Compared11:30 - Why Free Cash Flow Went Negative 20% This Quarter14:00 - Product Revenue vs. Subscription Revenue Breakdown16:30 - Reverse DCF: What the Market Is Pricing Into Everpure18:00 - Is Everpure Stock a Buy? Our Long-Term Thesis — If you want the reasoning behind more names like this one, Semiconductor Insider covers the process in more depth. Get access to all our research, weekly live Q&A events, and a growing set of tools to build your process: https://www.chipstockinvestor.com All our socials: https://linktr.ee/chipstockinvestor If you're getting value from the show, follow so you don't miss the next one. — Disclosure: Some links above are affiliate links. If you buy something through them, we might earn a little coffee money — thanks for helping us (Kasey) fuel our caffeine addiction. Content in this episode is for general information or entertainment only and is not specific or individual investment advice. Forecasts and information presented may not develop as predicted, and there is no guarantee any strategies presented will be successful. All investing involves risk, and you could lose some or all of your principal. CSI owns shares of Everpure.

    Pure Storage Is Now Everpure — and Free Cash Flow Just Went Negative (P Stock)

  3. 2d ago

    Procept Is Down 80% and the Tech Works — So Why Won't We Buy PRCT?

    Procept BioRobotics is down roughly 80% from its 2025 highs but the technology behind its Aquablation system genuinely works. So why won't we put PRCT in our portfolio? Procept (PRCT) has one of the more interesting razor-and-blade models in medtech: sell the Hydros or Aquabeam system, then earn recurring revenue from single-use handpieces used in every Aquablation procedure for benign prostatic hyperplasia (BPH). Gross margins run around 65%, Medicare covers the procedure in all 50 states, and the addressable market is roughly 40 million U.S. men — yet the company has never generated positive free cash flow and has cut guidance multiple times over the past year. In this episode, we size the real addressable market bottom-up using system counts and procedure volume, walk through the handpiece-to-procedure ratio that triggered a class-action lawsuit, compare Aquablation to competing BPH therapies like UroLift, Rezum, GreenLight, and traditional TURP, and dig into a foundational IP licensing structure that means Procept doesn't fully own the technology its business is built on. We also run a reverse DCF to see what growth rate the market is actually pricing in — and whether "cheap" is the right word for it. This is a preview of the research format inside Semiconductor Insider, including our new investment thesis checklist dashboard. TIMESTAMPS0:00 - Why PRCT Is Down 80% Despite Working Technology1:30 - How Aquablation Treats an Enlarged Prostate3:00 - Sizing the Real Market: 40 Million Men vs. Bottom-Up Math6:30 - The Business Model: Consumables, Margins, and Recurring Revenue8:00 - The Handpiece-to-Procedure Ratio and the Class Action Lawsuit10:00 - Competitive Landscape: UroLift, GreenLight, TURP, and da Vinci12:30 - Who Actually Pays? Medicare, CMS Codes, and Reimbursement Risk17:00 - The IP Problem: Why Procept Doesn't Own Its Core Patents19:00 - Guidance Cuts and Margin Trends Through Q2 202622:00 - Reverse DCF: What Growth Rate Is Priced In?26:00 - Investment Thesis Checklist and Final Verdict — If you want the reasoning behind more names like this one, Semiconductor Insider covers the process in more depth. Get access to all our research, weekly live Q&A events, and a growing set of tools to build your process: https://www.chipstockinvestor.com All our socials: https://linktr.ee/chipstockinvestor If you're getting value from the show, follow so you don't miss the next one. — Disclosure: Some links above are affiliate links. If you buy something through them, we might earn a little coffee money — thanks for helping us (Kasey) fuel our caffeine addiction. Content in this episode is for general information or entertainment only and is not specific or individual investment advice. Forecasts and information presented may not develop as predicted, and there is no guarantee any strategies presented will be successful. All investing involves risk, and you could lose some or all of your principal. CSI doesn't own shares of Procept BioRobotics.

    Procept Is Down 80% and the Tech Works — So Why Won't We Buy PRCT?

  4. 2d ago

    Why Oscar Health's 'Great Quarter' Isn't What It Looks Like

    Oscar Health looks like a screaming buy — growing revenue, growing members, positive free cash flow. So why does the market keep discounting it? We ran the numbers. Oscar Health (OSCR) just posted strong headline numbers: member growth accelerating past 3 million, revenue climbing, free cash flow positive. Health insurers don't get valued like typical growth stocks — and free cash flow is one of the most misleading metrics you can use here. In this episode, we break down why insurance float — not free cash flow — is the real driver of Oscar's balance sheet, how the medical loss ratio (MLR) caps profitability by regulation, and why receivables and payables to CMS matter more than most investors realize. We also walk through two reverse DCF scenarios on GAAP earnings per share — a 10-year model and a more aggressive 3-year model — to see what growth rate the market is actually pricing into OSCR today. Think of it as a masterclass in valuing any financials-driven business — insurance, banks, specialty finance — differently than you'd value a software or semiconductor company. We also give a first look at the new investment thesis checklist tool and segment/KPI dashboard inside Semiconductor Insider. TIMESTAMPS0:00 - Why Oscar Health Looks Cheap (And Why That's Misleading)1:04 - Revenue, Member Growth & Free Cash Flow Overview2:00 - The Problem: Free Cash Flow Isn't Real Cash Flow Here2:40 - Medical Loss Ratio Explained: The 80% Rule3:03 - Insurance Float 101 (The Berkshire Hathaway Playbook)4:38 - Reading the Balance Sheet: Premiums, Payouts & SG&A5:24 - CMS Receivables & Payables: The Hidden ACA Liability7:00 - Reverse DCF: 10-Year vs. 3-Year Growth Scenarios9:07 - Building a Custom Investment Thesis Checklist10:40 - Final Takeaway: How to Actually Value Oscar Health — If you want the reasoning behind more names like this one, Semiconductor Insider covers the process in more depth. Get access to all our research, weekly live Q&A events, and a growing set of tools to build your process: https://www.chipstockinvestor.com All our socials: https://linktr.ee/chipstockinvestor If you're getting value from the show, follow so you don't miss the next one. — Disclosure: Some links above are affiliate links. If you buy something through them, we might earn a little coffee money — thanks for helping us (Kasey) fuel our caffeine addiction. Content in this episode is for general information or entertainment only and is not specific or individual investment advice. Forecasts and information presented may not develop as predicted, and there is no guarantee any strategies presented will be successful. All investing involves risk, and you could lose some or all of your principal. CSI doesn't own shares of Oscar Health.

    Why Oscar Health's 'Great Quarter' Isn't What It Looks Like

  5. Sep 2

    Palo Alto Is Up 1,400% in a Decade — What Comes Next? (PANW FY2026)

    Palo Alto Networks (PANW) has been flying high into the end of FY2026. After a decade-long 1,400% run — capped by a broader cybersecurity rally following the Anthropic "Mythos moment" in early 2026 — what comes next? Nick breaks down how Palo Alto expanded from network security into cloud security through acquisitions, including the completed CyberArk deal (identity and access management), plus newer moves into AI agent security (Console) and observability (Embrace, complementing Chronosphere). On the financials: FY2026 revenue rose 24% to nearly $11.5B, with growth accelerating after CyberArk, while GAAP net income fell on stock-based compensation and amortization. Free cash flow came in just over $4.1B. We close with the next-12-months outlook for PANW as cybersecurity needs intensify for companies adopting more AI. — Access the fiscal.ai research terminal and get 15% off your membership with our link: https://fiscal.ai/csi Live event — new research platform sneak peek: join us Monday, September 7, 2026 at 7:00 AM Pacific for a live look at the new Chip Stock Investor research platform. Zoom: https://chipstockinvestor.zoom.us/j/98264538517?pwd=Hu3DuPQooFYZa7tYujMzUQcrAOIk6L.1 — or catch it live and on replay on our YouTube livestream. All our socials: https://linktr.ee/chipstockinvestor If you're getting value from the show, follow so you don't miss the next one. — Disclosure: Some links above are affiliate links. If you buy something through them, we might earn a little coffee money — thanks for helping us (Kasey) fuel our caffeine addiction. Content in this episode is for general information or entertainment only and is not specific or individual investment advice. Forecasts and information presented may not develop as predicted, and there is no guarantee any strategies presented will be successful. All investing involves risk, and you could lose some or all of your principal. CSI owns shares of Palo Alto Networks, CrowdStrike, and Fortinet.

  6. Sep 1

    Nokia Surged on Nvidia's Investment — Then Gave It Back. Buy the Dip? (NOK Q2 2026)

    Nokia stock surged on Nvidia's investment and AI RAN hype — then gave much of it back. We ran the numbers on NOK's Q2 2026 earnings to see if the sell-off is a buying opportunity or a warning sign. Nokia (NOK) has become one of 2026's most talked-about telecom equipment names after Nvidia's strategic investment and growing buzz around 6G and AI RAN (Radio Access Network) infrastructure. In this episode, we break down Nokia's Q2 2026 earnings, including the misleading telecom revenue chart, the real growth driver (AI and cloud products, up 105% year-over-year vs. just 4% for legacy telecom), and how the Infinera and Fenix Group acquisitions are repositioning Nokia as a vertically integrated optical communications and data center supplier. We also compare Nokia's free cash flow margin against internet infrastructure peers Cloudflare, Akamai, and Fastly, then run a reverse DCF to see what profit growth rate is already priced into the stock at a $55–56 billion market cap. With shares down significantly from 2026 highs, we explain why we're staying on the sidelines for now — and the price level where Nokia would become interesting again. TIMESTAMPS0:00 - New Research Platform & Live Event Announcement1:15 - CDN Series Wrap-Up: Why We're Holding Cloudflare2:00 - Nokia's Acquisition Spree: Fenix, Rapid, Infinera4:00 - Selling Fixed Wireless Access to Inseego5:00 - Q2 2026 Slide Deck: The Nvidia Investment Effect6:15 - The Misleading Telecom Revenue Chart7:30 - Real Growth Driver: AI and Cloud Up 105% YoY9:00 - Guidance, Margins, and Peer Comparison (CDN Stocks)11:20 - Reverse DCF: What Growth Rate Is Priced In?14:00 - Verdict: Why We're Passing (For Now) and Our Watch Price — Live event — new research platform sneak peek: join us Monday, September 7, 2026 at 7:00 AM Pacific for a live look at the new Chip Stock Investor research platform. Zoom: https://chipstockinvestor.zoom.us/j/98264538517?pwd=Hu3DuPQooFYZa7tYujMzUQcrAOIk6L.1 — or catch it live and on replay on our YouTube livestream. If you want the reasoning behind more names like this one, Semiconductor Insider covers the process in more depth. Get access to all our research, weekly live Q&A events, and a growing set of tools to build your process: https://www.chipstockinvestor.com All our socials: https://linktr.ee/chipstockinvestor If you're getting value from the show, follow so you don't miss the next one. — Disclosure: Some links above are affiliate links. If you buy something through them, we might earn a little coffee money — thanks for helping us (Kasey) fuel our caffeine addiction. Content in this episode is for general information or entertainment only and is not specific or individual investment advice. Forecasts and information presented may not develop as predicted, and there is no guarantee any strategies presented will be successful. All investing involves risk, and you could lose some or all of your principal. CSI doesn't own shares of Nokia.

  7. Aug 27

    AppLovin Fell 38% — Broken Thesis or Buying Opportunity? (APP Stock Deep Dive)

    AppLovin (APP) stock fell 38% after earnings — but is the digital advertising thesis actually broken, or is this a buying opportunity? Shares dropped roughly 38% after AppLovin's latest report, and investors are asking whether the mobile-ad-turned-AI-advertising company can keep growing into its valuation. In this episode, we map the entire digital ad supply chain, from the walled gardens (Google, Meta, Amazon) that control roughly two-thirds of digital ad spend, down to the demand-side and supply-side platforms competing around them. We trace AppLovin's path from a 2012 mobile-game user-acquisition tool into one of the largest software companies in digital advertising, powered by its Axon 2.0 AI algorithm. We cover the sale of its game studios to Tripledot, its push into e-commerce through a Shopify integration, and why the market is worried about decelerating revenue growth alongside historically high operating and free cash flow margins. Using our new Custom Supply Chain tool, we compare AppLovin against Omnicom, The Trade Desk, Google, and Magnite to show where value actually accrues and share our own take as long-time shareholders. If you're deciding whether AppLovin is a buy after this sell-off, this is the fundamentals-first framework to make that call yourself. If you want the reasoning behind more names like this one, Semiconductor Insider covers the process in more depth. Get access to all our research, weekly live Q&A events, and a growing set of tools to build your process: https://www.chipstockinvestor.com All our socials: https://linktr.ee/chipstockinvestor If you're getting value from the show, follow so you don't miss the next one. — Disclosure: Some links above are affiliate links. If you buy something through them, we might earn a little coffee money — thanks for helping us (Kasey) fuel our caffeine addiction. Content in this episode is for general information or entertainment only and is not specific or individual investment advice. Forecasts and information presented may not develop as predicted, and there is no guarantee any strategies presented will be successful. All investing involves risk, and you could lose some or all of your principal. CSI owns shares of AppLovin.

  8. Aug 25

    ENVX Stock: CEO Quits Days After Q2 Earnings Miss

    Enovix stock just hit an all-time low — and then the CEO abruptly resigned. We break down the Q2 2026 earnings, the cash runway, and whether this small bet is still worth holding. Enovix (ENVX) stock cratered to an all-time low following its Q2 2026 earnings update, and just days later, CEO Dr. Raj Talluri announced his departure — poached by Kulicke & Soffa, a fast-growing advanced packaging and semiconductor equipment company. In this episode, we break down what's really happening with Enovix's silicon-anode lithium-ion battery technology, including the jump from silicon to silicon oxide to silicon-carbon composite chemistry that pushed cycle life from as few as 10 charges to over 1,000. We cover the company's smartphone qualification progress (including a leading Chinese OEM), its commercial smart glasses order, and why revenue guidance of roughly $9.5 million against higher capital expenditures spooked the market. We also dig into the balance sheet: $476 million in cash and equivalents, $74 million in longer-term investments, over $520 million in debt, and a cash burn rate that raises real questions about future capital raises. Is this pre-revenue R&D story finally turning the corner into commercialization — or is production hell just getting started? We share why this remains a small, high-risk position in our portfolio and what we're watching heading into 2027. — If you want the reasoning behind more names like this one, Semiconductor Insider covers the process in more depth. Get access to all our research, weekly live Q&A events, and a growing set of tools to build your process: https://www.chipstockinvestor.com All our socials: https://linktr.ee/chipstockinvestor If you're getting value from the show, follow so you don't miss the next one. — Disclosure: Some links above are affiliate links. If you buy something through them, we might earn a little coffee money — thanks for helping us (Kasey) fuel our caffeine addiction. Content in this episode is for general information or entertainment only and is not specific or individual investment advice. Forecasts and information presented may not develop as predicted, and there is no guarantee any strategies presented will be successful. All investing involves risk, and you could lose some or all of your principal. CSI owns shares of Enovix.

See All (489)

4.6
out of 5
14 Ratings

About

Semiconductors are the heart of the modern economy. These small devices that manipulate the flow of electricity run everything from our PCs and smartphones to our cars to manufacturing. The semiconductor industry is at an inflection point of renewed growth, powering new movements like generative AI and electric vehicles. The Chip Stock Investor Podcast explores how semiconductors work, and especially the business of chips. Follow Nicholas and Kasey to learn how chip technology has become the engine of the world, and how to invest in its growth.

Information

  • Creator
    Nicholas Rossolillo; Kasey Rossolillo
  • Years Active
    2023 - 2026
  • Episodes
    489
  • Rating
    Clean
  • Copyright
    © Nicholas Rossolillo; Kasey Rossolillo
  • Show Website
    Chip Stock Investor Podcast

You Might Also Like